Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 April 2022 - 9:00PM
Business Wire
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage
biopharmaceutical company developing and delivering transformative
therapies for cancer patients against novel epigenetic targets,
today announced that the Company has granted equity awards to
Jerald Korn, the Company’s Chief Operating Officer, with a grant
date of April 1, 2022, as equity inducement awards outside of the
Company’s 2013 Stock Incentive Plan and material to Mr. Korn’s
acceptance of employment with the Company. The equity awards were
approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Mr. Korn received options to purchase an aggregate of 800,000
shares of Epizyme common stock. The options have an exercise price
of $1.14 per share, which is equal to the closing price of Epizyme
common stock on April 1, 2022, the grant date of the options. The
options will vest as to 25% of the underlying shares on the first
anniversary of the grant date and as to an additional 2.0833% of
the shares at the end of each successive month following the first
anniversary of the grant date, such that the shares underlying the
options granted to Mr. Korn will be fully vested on the fourth
anniversary of the grant date, subject to Mr. Korn’s continued
employment with Epizyme on such vesting dates.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage
biopharmaceutical company committed to its mission of rewriting
treatment for cancer through novel epigenetic medicines. The
Company is focused on creating medicines that are targeted at
specific causes of diseases, that are orally administered,
tolerable, easy to take and based on a deep understanding of the
patients that may benefit from them. The Company aspires to change
the standard-of-care for patients and physicians by developing
medicines with fundamentally new mechanisms of action. For more
information, visit www.epizyme.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406005019/en/
Media: Erin Graves media@epizyme.com (617) 500-0615
Investors: Caitlin Stern cstern@realchemistry.com
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about Epizyme Inc (NASDAQ): 0 recent articles
More Epizyme, Inc. News Articles